Ocular Drug Delivery Devices Market Analysis

  • Report ID: 4029
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Ocular Drug Delivery Devices Segmentation

Disease Type (Glaucoma, Diabetic Macular Edema, Diabetic Retinopathy, Macular Degeneration, Cataract, Refractive Issues)

The market is segmented and analyzed for demand and supply by disease type into glaucoma, diabetic macular edema, diabetic retinopathy, macular degeneration, cataract, refractive issues, and others out of which, the cataract segment is anticipated to hold a substantial share in the global market over the forecast period on account of high cases of cataract globally. Moreover, various government initiatives to spread awareness about cataracts, are anticipated to boost the segment growth. The increasing geriatric population increases the risk of cataracts are estimated to propel the market growth. The market growth is attributed to poor medical facilities and increasing incidence of other disease conditions such as hypertension, diabetes, eye trauma, and eczema. As per the estimations, globally over 15 million population with age 50 and above are suffering from blindness as of 2020. 

Type (Topical, Iontophoresis, Ocular Insert, Intraocular Implants, In-situ Gel)

The global ocular drug delivery devices market is also segmented and analyzed for demand and supply by type into topical, iontophoresis, ocular insert, intraocular implants, in-situ gel, and others. Amongst these segments, the intraocular implants segment is expected to garner a significant share. The increasing mortality rate owing to the infections of bacteria and viruses and vision impairment are estimated to boost the market growth. The Increasing screentime of people with work-from-home jobs, IT jobs, software jobs, and growing animation jobs is also driving the growth of the market as per the market analysis. The disposable income of people leads to increased use of smartphones, television (TV), and gaming stations which increase the risk of eye disorders and occurrence of blindness among people. As of 2022 reports, more than 50% of Americans spend time watching TV for one to four hours a day, and over 20% watch TV more than four hours per day.

Our in-depth analysis of the global market includes the following segments:

      By Type

  • Topical
  • Iontophoresis
  • Ocular Insert
  • Intraocular Implants
  • In-situ Gel
  • Others

       By Drug Form

  • Solution
  • Suspension
  • Emulsion
  • Others

       By Diseases Type

  • Glaucoma
  • Diabetic Macular Edema
  • Diabetic Retinopathy
  • Macular Degeneration
  • Cataract
  • Refractive Issues
    • Myopia
    • Hypermetropia
    • Presbyopia
  • Others

       By End User

  • Drug Stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers
  • Homecare Centers
  • Others
 

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of ocular drug delivery devices is estimated at USD 17.82 billion.

The ocular drug delivery devices market size was valued at USD 15.69 billion in 2024 and is set to exceed USD 43.71 billion by 2037, expanding at over 8.2% CAGR during the forecast period i.e., between 2025-2037. Increasing prevalence of ocular diseases and growing awareness amongst people regarding vision impairment will fuel the market growth.

North America industry is poised to dominate majority revenue share by 2037, owing to growing cases of cataracts and diabetes-related visual conditions in the region.

The major players in the market are Bausch Health Companies Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Kiora Pharmaceuticals, Inc., Graybug Vision Inc., Apellis Pharmaceuticals, Inc., Implanet Company, Aerie Pharmaceuticals Inc., EyePoint Pharmaceuticals, Inc., Protalix BioTherapeutics
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos